Jazz Pharmaceuticals JAZZ Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's shares (diluted)?
- Jazz Pharmaceuticals (JAZZ) reported shares (diluted) of 66.1M in Q1 2026.
- How has Jazz Pharmaceuticals's shares (diluted) changed year-over-year?
- Jazz Pharmaceuticals's shares (diluted) increased by 8.4% year-over-year, from 61M to 66.1M.
- What is the long-term trend for Jazz Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's shares (diluted) has grown at a 0.6% compound annual growth rate (CAGR), from 238.8M to 244.8M.
- What does shares (diluted) mean?
- The average number of shares that would exist if all potential stock-based awards were converted into actual shares.
- How do you interpret shares (diluted)?
- A rising count suggests increased dilution from employee compensation or financing activities, which can pressure per-share earnings metrics.
- How does shares (diluted) compare across companies?
- Standardized metric; critical for assessing the impact of equity-based incentive plans on shareholder value.